Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Operating Expenses (2017 - 2025)

Sutro Biopharma's Operating Expenses history spans 9 years, with the latest figure at $58.2 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 23.92% year-over-year to $58.2 million; the TTM value through Sep 2025 reached $291.2 million, changed 0.08%, while the annual FY2024 figure was $300.5 million, 23.66% up from the prior year.
  • Operating Expenses for Q3 2025 was $58.2 million at Sutro Biopharma, down from $67.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $85.9 million in Q1 2025 and bottomed at $33.7 million in Q1 2021.
  • The 5-year median for Operating Expenses is $57.9 million (2022), against an average of $58.5 million.
  • The largest annual shift saw Operating Expenses skyrocketed 51.87% in 2021 before it fell 23.92% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $45.7 million in 2021, then increased by 26.62% to $57.9 million in 2022, then grew by 21.98% to $70.6 million in 2023, then rose by 13.46% to $80.1 million in 2024, then dropped by 27.37% to $58.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Operating Expenses are $58.2 million (Q3 2025), $67.1 million (Q2 2025), and $85.9 million (Q1 2025).